Ucb Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ucb (US): 14 reconciled FDA prescription therapies (39.3% 2025 to 2030 cliff risk), $1.91B 2024 CMS Part D & Medicaid spend, and 79 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies14
2025 to 2030 Patent-Cliff Revenue Exposure39.3%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$1.91B
2024 Medicare Part D Spend$1.01B
2024 Medicaid Spend$895.6M
California HCAI SB 17 Filings79 WAC filings (max 20.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.